Feloprentan is an endothelin receptor antagonist.

Butilfenin is N-substituted iminodiacetic acid derivative that was studied as tridentate ligand to form a technetium-99m complex.

Metaterol is a beta-adrenoceptor agonist. It exerts sympathomimetic and broncholytic properties.

Metheptazine was studied as an analgesic agent.

Norleucine (L-norleucine) is a 2-aminohexanoic acid is an alpha-amino acid that is caproic acid substituted by an amino group at position 2. It derives from a hexanoic acid. It is used experimentally to study protein structure and function. Norleucine appears to inhibit bacterial growth due to incorporation into proteins in place of methionine, as the analogue inhibits methionine incorporation but does not significantly reduce its synthesis. L-norleucine had antiviral activity in thermophile. In vitro and in vivo assays revealed that L-norleucine significantly suppressed metastasis of gastric and breast cancer cells. L-norleucine interacted with hnRNPA2/B1 protein to inhibit the expressions of Twist1 and Snail, two inhibitors of E-cadherin, and promote the E-cadherin expression, leading to the inhibition of tumor metastasis.

Cefuracetime is an impurity of Cefuroxime, which is an antibacterial agent.

Carbazeran is a potent PDE-II and PDE-III inhibitor. Potently inhibits cAMP hydrolysis. Shows chronotropic and inotropic effect in vivo (EC50 = 100 μM, ionotropic effects, independent of adrenergic mechanisms). Carbazeran is a potent cardiac stimulant. Phosphodiesterase inhibition and elevation of intracellular cyclic AMP concentration may be involved, at least in part, in carbazeran`s cardiac effect.

Nesosteine is a mucoregulatory agent. Nesosteine reduced the viscosity of tracheobronchial mucus in rabbits made bronchitic by H2SO4 aerosol and markedly increased mucoproduction in healthy animals. Nesosteine was more active than the best known mucolytic/mucoregulatory drugs, such as sobrerol, N-acetylcysteine and mercaptopropionylglycine. The fluidifying activity of the drug was also demonstrated in vitro (pig's gastric mucin), although this proved to be less marked than in vivo. Nesosteine reduced the amount of total proteins of the tracheobronchial mucus, acting on albumin, alpha 1, alpha 2, beta and gamma mucoproteins.

Amiglumide [CR 1795] is an amino acid derivative with cholecystokinin A antagonist activity. It has potential use for treating gastrointestinal disorders, pancreatitis and biliary dyskinesia. Amiglumide was developed in preclinical trials with Rottapharm in Italy.